Morbidity during hospitalization: Can we predict it?

Charlson, Mary E.; Sax, Frederic L.; MacKenzie, C. Ronald; Braham, Robert L.; Fields, Suzanne; Douglas, R. Gordon

doi:10.1016/0021-9681(87)90107-x

Cited by 160 publications

(114 citation statements)

References 16 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…We retrospectively collected patient demographics, cancer diagnosis details, symptoms, medical comorbidities, score on the Charlson comorbidity index 9 , and baseline Eastern Cooperative Oncolog y Group performance status 10 based on the initial oncology consultation and clinic notes. Treatment details, toxicities, response, recurrence, and survival outcomes were obtained from several documented assessments during treatment and follow-up.…”

Section: Data Collectionmentioning

confidence: 99%

Shifting Practice in Definitive Chemoradiation for Localized Esophageal Cancer

Biagi

Hopman

et al. 2017

Current Oncology

View full text Add to dashboard Cite

show abstract

Section: Data Collectionmentioning

confidence: 99%

Shifting Practice in Definitive Chemoradiation for Localized Esophageal Cancer

Biagi

Hopman

et al. 2017

Current Oncology

View full text Add to dashboard Cite

show abstract

“…To give a descriptive analysis of this cohort's comorbidity burden, we used the Charlson comorbidity index (Charlson score;Charlson et al, 1987). The Charlson score is a widely used comorbidity scale validated to correlate with 1-year mortality risk in cancer patients (Newschaffer et al, 1997;Reid et al, 2001).…”

Section: Pretreatment Evaluationmentioning

confidence: 99%

Combined modality chemoradiation in elderly oesophageal cancer patients

et al. 2007

View full text Add to dashboard Cite

We present a single institution experience with 5-FU, mitomycin-C based chemoradiation for the primary treatment of elderly patients with oesophageal cancer. Twenty-five patients with a median age of 77 years (range 66 -88) with a diagnosis of stage II -III squamous cell or adenocarcinoma of the oesophagus were treated at Memorial Sloan Kettering from 1996 to 2001 with two cycles of concurrent 5-FU, mitomycin-C and 50.4 Gy. Owing to age and comorbidity, these patients were not considered surgical candidates. The Charlson comorbidity score was used to evaluate patient comorbidity. Nine patients (36%) experienced grade 3 -4 haematologic toxicity. Of the 23 patients evaluable for response, 17 patients (68%) had a negative post-treatment endoscopy and CT scan without evidence of progressive disease. Eleven patients (44%) are alive and 10 (40%) remain without evidence of recurrent or progressive oesophageal cancer at a median follow-up of 35 months. The median overall survival was 35 months and 2-year survival 64%. There was no significant difference in overall survival between Charlson score p2 and those with a score X2 (P ¼ 0.10). Similar survival was observed for patients with adenocarcinoma or squamous carcinoma. Primary chemoradiation with two cycles of 5-FU, mitomycin-C, and 50.4 Gy in elderly patients is an active regimen with moderate toxicity, despite the advanced age and heavy comorbidity burden of this cohort. Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone.

show abstract

“…Based on the initial oncology consultation and clinic notes for each patient, we retrospectively collected demographics, details of the cancer diagnosis, symptoms, medical comorbidities, score on the Charlson comorbidity index (cci) 18 , and Eastern Cooperative Oncology Group (ecog) performance status 19 . Treatment details, toxicities, response, recurrence, and survival outcomes were obtained for various time points during treatment and follow-up.…”

Section: Data Collectionmentioning

confidence: 99%